• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    4/24/25 4:00:10 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email
    Form 8-K
    0001114483 False 0001114483 2025-04-24 2025-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  April 24, 2025

    _______________________________

     

    INTEGER HOLDINGS CORPORATION

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware1-1613716-1531026
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

    5830 Granite Parkway, Suite 1150

    Plano, Texas 75024

    (Address of Principal Executive Offices) (Zip Code)

    (214) 618-5243

    (Registrant's telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value per shareITGRNew York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (b), (c), (d) and (e)               On April 21, 2025, the Board of Directors (the “Board”) of Integer Holdings Corporation (the “Company”) approved a planned leadership succession and transition plan with Joseph W. Dziedzic, the Company’s President and Chief Executive Officer (“CEO”), under which Mr. Dziedzic will retire as President and CEO and step down from the Board, effective October 24, 2025.  On April 21, 2025, the Board also appointed Payman Khales, the Company’s current Chief Operating Officer, to succeed Mr. Dziedzic as President and CEO of the Company in connection with Mr. Dziedzic’s retirement process.

         To help ensure a smooth leadership transition under this process, Mr. Dziedzic will continue to serve as President and CEO until October 24, 2025, when Mr. Dziedzic will transition to non-executive employment with the Company as a Special Advisor, and Mr. Khales will succeed Mr. Dziedzic as President and CEO.  As part of his role as CEO through October 24, 2025 and thereafter during his service as Special Advisor, Mr. Dziedzic is expected to assist and prepare Mr. Khales to succeed him as President and CEO and work on other transition matters.  Mr. Dziedzic’s Special Advisor service is expected to continue until March 31, 2026, on which date he is expected to retire from the Company. Upon his transition to non-executive employment on October 24, 2025, Mr. Dziedzic will also resign from his service as a director on the Board, and the Company expects that Mr. Khales will be elected to the Board on that same day.

         Mr. Khales, age 55, joined the Company on February 20, 2018, and served as President, Cardio & Vascular until October 2024, when he began to transition to the role of Chief Operating Officer. Mr. Khales is also the leader for Integer’s Customer Operational strategic imperative. Prior to joining the Company, Mr. Khales was the President of the Environmental Technologies Segment at CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments, between 2014 and 2017. Prior to that, Mr. Khales was employed by Ingersoll Rand Company, a diversified industrial products company, where he held a variety of different roles in the United States and Canada, including Vice President Product Management for the global Power Tools division between 2012 and 2014, and Vice President Strategic Accounts & Channels between 2010 and 2011.

         In connection with this executive transition, Mr. Dziedzic will receive a base salary for any Special Advisor service equal to 100% of his annual CEO base salary rate, but he will not be eligible for a grant of equity awards in or for fiscal year 2026, nor will he be eligible to participate in any annual or other short-term incentive compensation program of the Company for fiscal year 2026. The term of Mr. Dziedzic’s current employment agreement with the Company is also being extended until the end of March 30, 2026 to coordinate with his retirement.

         In connection with Mr. Dziedzic’s retirement, and in exchange for a release of claims and an extension of the term of his post-termination restrictive covenants from 24 months to 36 months, the Board will modify Mr. Dziedzic’s outstanding time-based restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”) to receive “retirement eligibility” treatment. Under this retirement eligibility treatment, Mr. Dziedzic’s outstanding RSUs will vest in full and his PRSUs will vest on a prorated basis under the terms of the applicable award agreements based on the Company’s actual performance for such PRSUs (the “Retirement Treatment”).  The Retirement Treatment equates to essentially lowering the retirement age prong of the “retirement eligible” definition from 59.5 to 57 (but Mr. Dziedzic would otherwise satisfy the combination of age plus service requirement of 69.5).  The Retirement Treatment is being provided due to Mr. Dziedzic’s proximity to the qualifying retirement age, but also in recognition of his years of valuable service to the Company, as well to help compensate and motivate Mr. Dziedzic for his role in the transition process and his service as Special Advisor to help implement a smooth and seamless transition for the CEO role.  These PRSUs will be subject to the Company’s applicable compensation clawback policies and provisions after Mr. Dziedzic’s retirement.

         After the end of Mr. Dziedzic’s employment, he will receive payment of his other accrued benefits, including earned but unpaid base salary, accrued but unused vacation days in accordance with Company policy, payment (if any) of his earned but unpaid short-term cash incentive compensation under the Company’s fiscal year 2025 short-term incentive compensation program based on actual performance, and reimbursement of unreimbursed but reimbursable expenses, as required under the current terms of Mr. Dziedzic’s employment agreement with the Company (collectively the “Accrued Benefits”). Mr. Dziedzic will also be reimbursed for reasonable legal fees and expenses in connection with this arrangement up to $25,000.

         If Mr. Dziedzic’s employment is terminated without Cause (as defined in the current employment agreement between the Company and Mr. Dziedzic) by the Company prior to March 31, 2026, he will be entitled to receive, in exchange for a release of claims (i) payment of a cash lump sum equal to the balance of the base salary he would have earned had he remained employed with the Company until March 31, 2026, (ii) the Retirement Treatment, with such outstanding RSUs and PRSUs treated as if Mr. Dziedzic had remained employed with the Company until March 31, 2026, and (iii) payment of any earned but unpaid short-term cash incentive compensation under the Company’s fiscal year 2025 short-term incentive compensation program as if he remained employed through March 31, 2026, based on actual performance and paid generally at the same time as the Company’s other executives.  Mr. Dziedzic will also be entitled to receive the other Accrued Benefits as if he remained employed through March 31, 2026. This compensation would be provided in lieu of and in full satisfaction of the severance compensation and benefits otherwise provided for under his current employment agreement.

         On April 22, 2025, the Company and Mr. Dziedzic entered into an Executive Retirement Agreement to memorialize the terms of this arrangement.

    Item 7.01. Regulation FD Disclosure.

         On April 24, 2025, the Company issued a press release announcing the CEO succession plan whereby Mr. Dziedzic will retire as President and CEO and Mr. Khales has been appointed as President and CEO, in each case effective October 24, 2025. A copy of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

         In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific references in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit Number Description of Exhibit
       
    99.1 Press Release dated April 24, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     INTEGER HOLDINGS CORPORATION
       
      
    Date: April 24, 2025By: /s/ Lindsay K. Blackwood        
      Lindsay K. Blackwood
      Senior Vice President, General Counsel and Corporate Secretary
      

     

    Get the next $ITGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    12/3/2024$160.00Overweight
    Wells Fargo
    7/16/2024$135.00Outperform
    Oppenheimer
    5/15/2024$137.00Buy
    Truist
    4/15/2024$105.00 → $135.00Neutral → Buy
    BofA Securities
    3/14/2024$137.00Buy
    CL King
    2/6/2024$125.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integer to Present at Bank of America Securities Health Care Conference on May 14

      PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT. A live webcast of the presentation will be accessible under "News & Events" on the Investor Relations section of the Integer website at investor.integer.net. Learn more about Integer at www.integer.net. About Integer®Integer Holdings Corporation (NYSE:I

      4/29/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Announces CEO Succession Plan

      ~ Joseph Dziedzic to retire as President and CEO ~~ Payman Khales appointed President and CEO effective October 24, 2025 ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. "We

      4/24/25 8:01:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation Reports First Quarter 2025 Results

      ~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) Sales increased 7% to $437 million, with organic growth of 6%.GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%.GAAP income (loss) from continuing operations decreased $43 million to a

      4/24/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Financials

    Live finance-specific insights

    See more
    • Integer Announces CEO Succession Plan

      ~ Joseph Dziedzic to retire as President and CEO ~~ Payman Khales appointed President and CEO effective October 24, 2025 ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. "We

      4/24/25 8:01:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation Reports First Quarter 2025 Results

      ~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) Sales increased 7% to $437 million, with organic growth of 6%.GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%.GAAP income (loss) from continuing operations decreased $43 million to a

      4/24/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Schedules First Quarter 2025 Earnings Release and Conference Call for April 24, 2025

      PLANO, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for first quarter 2025 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, April 24, 2025. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details: Date: Thursday, April 24, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 3120125Webcast Registration: ITGR Q1 2025 Ea

      3/27/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Integer Announces Board Leadership Transition

      PLANO, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, announced today that Bill R. Sanford will be retiring as Chair of the Integer Board of Directors at the conclusion of the Company's 2022 annual meeting of stockholders, which is scheduled to be held on May 18, 2022. Commensurate with this carefully planned transition, the Board of Directors plans to appoint current long-standing Integer Board member Pamela G. Bailey to serve as the next Chair of the Board. "On behalf of the Integer Board of Directors, I wish to thank Bill for his immense contribution and insightful leadership over the past 22 ye

      3/17/22 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/9/24 9:59:01 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      1/30/24 1:15:44 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/10/23 2:42:23 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Integer Holdings with a new price target

      Raymond James initiated coverage of Integer Holdings with a rating of Outperform and set a new price target of $145.00

      3/28/25 8:19:38 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings downgraded by Oppenheimer

      Oppenheimer downgraded Integer Holdings from Outperform to Perform

      2/21/25 6:56:47 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo resumed coverage on Integer Holdings with a new price target

      Wells Fargo resumed coverage of Integer Holdings with a rating of Overweight and set a new price target of $160.00

      12/3/24 7:34:30 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Integer Holdings Corporation

      10-Q - Integer Holdings Corp (0001114483) (Filer)

      4/24/25 5:12:21 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      4/24/25 4:00:10 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      4/24/25 8:07:31 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CRM & Neuro Stephens Jim converted options into 491 shares and covered exercise/tax liability with 120 shares, increasing direct ownership by 41% to 1,274 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      5/16/25 4:12:35 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Carr Terence

      3 - Integer Holdings Corp (0001114483) (Issuer)

      5/15/25 8:06:24 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EVP, Chief Financial Officer Smith Diron converted options into 2,063 shares and covered exercise/tax liability with 706 shares, increasing direct ownership by 26% to 6,582 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      5/12/25 4:59:27 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care